Compare Cytokinetics Inc (CYTK) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs ProShares UltraPro S&P500 — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while ProShares UltraPro S&P500 trades at $154.09. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | UPRO | |
|---|---|---|
Market Cap | $10.78B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $87.26 | $155.10 |
52-Week Low | $34.31 | $89.29 |
Enterprise Value | $10.88B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
UPRO trades at $155.10, up 1.72% on the day, with a bullish technical signal from moving averages and a neutral oscillator reading. The stock faces resistance near $156 and support at $154, while the RSI indicates potential overbought conditions. Recent news highlights S&P 500 strength, with JPMorgan raising its 2026 target to 8,000, driven by AI-driven earnings growth and robust corporate performance.
The outlook remains positive amid strong market momentum, but risks include overvaluation concerns and sensitivity to economic data. Upside potential hinges on sustained earnings growth, while pullbacks may occur if breadth weakens or inflation fears resurface.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
